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Online risk prediction tools for common cancers are now easily accessible and widely used by patients
and doctors for informed decision-making concerning screening and diagnosis. A practical problem
is as cancer research moves forward and new biomarkers and risk factors are discovered, there is a
need to update the risk algorithms to include them. Typically, the new markers and risk factors
cannot be retrospectively measured on the same study participants used to develop the original
prediction tool, necessitating the merging of a separate study of diﬀerent participants, which may be
much smaller in sample size and of a diﬀerent design. Validation of the updated tool on a third
independent data set is warranted before the updated tool can go online. This article reports on the
application of Bayes rule for updating risk prediction tools to include a set of biomarkers measured
in an external study to the original study used to develop the risk prediction tool. The procedure is
illustrated in the context of updating the online Prostate Cancer Prevention Trial Risk Calculator to
incorporate the new markers %freePSA and [-2]proPSA measured on an external case–control study
performed in Texas, U.S.. Recent state-of-the art methods in validation of risk prediction tools and
evaluation of the improvement of updated to original tools are implemented using an external
validation set provided by the U.S. Early Detection Research Network.
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prediction; Validation.
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1 Introduction
Risk prediction tools for diagnosis, prognosis and treatment of disease are now widely
available on the Internet. Two of the more prominently used online risk tools are the Framingham
study 10-year risk calculator for cardiovascular disease (Grundy et al., 2004) and the Gail model
Breast Cancer Risk Assessment Tool (BRCAT, Gail et al., 1989, 2007). Emergence of such tools on
the Internet has expedited translational medicine, more quickly bringing scientiﬁc discoveries from
the laboratories to the clinic, as well as increased the practice of informed joint decision-making
between doctors and their patients concerning individual health management.
In the realm of early cancer detection, high-throughput technologies are now the routine and
have brought about mass discoveries of potential cancer markers. Networks of laboratory research
centers, such as the Early Detection Research Network (EDRN), have mobilized to expedite
laboratory discoveries through validation phases (Pepe et al., 2001). As new cancer biomarkers are
discovered and validated, the question arises as to how they can be incorporated into the existing
online risk prediction tools, tools which have been created on strong foundations based on extensive
analyses of prior large cohorts. Typically, the newly discovered markers cannot be retrospectively
measured on sera or other samples stored from participants of the original study or no such
biological samples were stored in the ﬁrst place. Hence, ﬁtting an expanded prediction model that
includes the new markers on the same set of data used to develop the original prediction tool is not
an option. An additional challenge is that due to cost considerations relatively new biomarkers are
typically only measured on smaller retrospective case–control studies. Although the same markers
and risk factors from the original risk prediction tool may be measured alongside the new markers
in the smaller study so that an expanded model could in principle be constructed on the smaller
study, it would seem imprudent to discard the large foundation on which the original risk prediction
tool was built.
Fortunately, the Bayesian paradigm is exactly suited for updating prior knowledge with newly
available data through the transformation of prior odds to posterior odds via the likelihood ratio.
Likelihood ratios have been intricately investigated as a means in and of themselves for evaluating
the diagnostic performance of a single marker in the case of a dichotomous marker by Janssens
et al. (2005) and a continuous marker by Gu and Pepe (2009, 2011). Steyerberg (2010) reviewed
these cases as part of a general paradigm. A fully Bayesian approach for updating prior risks
through likelihood ratios to obtain posterior risks was implemented by Ankerst et al. (2008) to
incorporate the urine marker PCA3 into the Prostate Cancer Prevention Trial Risk Calculator
(PCPTRC) and by Skates et al. (2001) to estimate risk of ovarian cancer based on longitudinal
CA125 measurements. The case study to be evaluated in this report adds to the prior literature by
considering the incorporation of two or more possibly dependent biomarkers into a risk tool. It
assumes that the markers can be transformed to follow multivariate Normal distributions and
speciﬁes distinct variance-covariance matrices for the joint marker distributions in the cancer and
non-cancer participants. Viewed as a decision rule for classifying subjects as diseased versus non-
diseased, likelihood ratios modeled in this fashion correspond to quadratic discriminant analysis as
opposed to linear discriminant analysis, which speciﬁes that the variance–covariance matrices of the
two populations are the same (Izenman, 2008, pp. 257–258).
The motivation for the case study was a need to update an existing online tool, the PCPTRC, for
two markers that have recently emerged in early prostate cancer detection research. The PCPTRC
had been published online in 2006 following completion of a large prevention trial, and provides a
simple-to-use accessible device for urologists and patients to calculate their risk of prostate cancer
based on the established risk factors prostate-speciﬁc antigen (PSA), digital rectal exam (DRE),
ﬁrst-degree family history of prostate cancer and history of a prior negative prostate biopsy
(Thompson et al., 2006). Since its publication, the PCPTRC has been widely implemented and
validated, and in 2010 the American Cancer Society recommended it in its guidelines for prostate
cancer screening (Wolf et al., 2010). Using data from a recent case–control study, the San Antonio
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Biomarkers Of Risk of prostate cancer (SABOR) study, reporting on two promising new prostate
cancer biomarkers, %freePSA and [-2]proPSA, (Liang et al., 2011), this case study ﬁrst shows how
the PCPTRC is updated to incorporate new markers via likelihood ratios modeled via multivariate
normal distributions. The updated PCPTRC is then validated on a separate EDRN validation set
arising from patients visiting university hospitals in Michigan, Massachusetts and Maryland, U.S.
using state-of-the-art evaluation criteria for risk prediction tools including measures of dis-
crimination, calibration, clinical net beneﬁt and the integrated discrimination index (IDI).
2 Bayesian updating of risk models to incorporate new risk factors
The Bayesian paradigm begins with an existing risk model for the presence or absence of cancer,
called the prior model, which is based on some established risk factors. The prior risk of cancer from
the prior model is converted into the prior odds of cancer. A likelihood ratio for new markers
conditional on the established risk factors is calculated based on some external study to that used in
constructing the prior model, which is then multiplied by the prior odds to obtain the posterior odds
of cancer. The general concept applies to the prediction of any binary endpoint with corresponding
appropriate model, and to any types of new markers with the corresponding appropriate joint
models. However, to keep to the issues at hand, the speciﬁc context and models of the case study
will be used for the deﬁnition of the method.
A risk model for cancer constructed by logistic regression yields the estimate of the prior odds of
cancer
PðCancerjXÞ
PðNo CancerjXÞ ¼ expðb
0XÞ
dependent upon a vector of log odds ratios b for a group of established risk factors X. In this case
study as in much of the applications surrounding online prediction tools, the prior risk model has
been developed on a large prospective population so that b accurately estimates the population
prevalence and relationship of risk factors to cancer with small variance.
Next, an external case–control or prospective study provides information on the association
between cancer and the same risk factors X, or subset thereof, and additionally, new markers Y. It is
assumed that Y is a vector of continuous markers that can be transformed to approximately follow
a multivariate normal distribution among the cancer cases and controls so that multivariate
regression of Y on X can be performed to estimate the numerator and denominator of the likelihood
ratio (LR):
LR ¼ PðY jCancer;XÞ
PðY jNo Cancer;XÞ ¼
cancerj j1=2exp  12 ðY  mcancerÞ01cancerðY  mcancerÞ
 
no cancerj j1=2exp  12 ðY  mno cancerÞ01no cancerðY  mno cancerÞ
  ;
where mcancer and mno cancer are the least-square estimates of the linear regression means, E(Y|Cancer,
X)5Xgcancer and E(Y|No Cancer, X)5Xgno cancer, and Scancer and Sno cancer are unbiased
estimators of the variance–covariance matrices from the multivariate regression applied to cases and
controls, respectively. Multivariate regression can be performed in R using the lm command and
model selection via the Wilks’ lambda test using the anova.mlm command with test5
’’Wilks’’.
Bayes rule then applies for updating the prior odds to the posterior odds through the likelihood
ratio:
Posterior Odds ¼Likelihood Ratio Prior Odds;
PðCancerjX ;YÞ
PðNo CancerjX ;YÞ ¼
PðY jCancer;XÞ
PðY jNo Cancer;XÞ 
PðCancerjXÞ
PðNo CancerjXÞ :
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The posterior odds are converted into posterior risks with their conﬁdence intervals calculated
from the variance covariance matrices of the component models: Var(all parameters)5
diag(Var(b), Var(gcancer), Var(Scancer), Var(gno cancer), Var(Sno cancer)), using the delta method
(implementable via the deltamethod function in the R package msm) or the parametric bootstrap.
3 Validation
As noted in extensive philosophical discussions by Anscombe (1967) and Chatﬁeld (1995) and
realized extensively in medical practice, the only real validation of a prediction model is con-
ﬁrmation by a completely independent set of observations collected on a diﬀerent set of patients
from diﬀerent centers by diﬀerent investigators. Recently, Steyerberg et al. (2010) provided a
clarifying review of evaluation methods for risk prediction models, separating evaluation metrics
according to whether they measure discrimination, calibration or both. The purpose of this section
is to review the latest state-of-the-art in validation principles for risk prediction tools and for
comparing updating risk tools to existing tools.
Typically the way risk prediction tools, or diagnostic markers in general, are applied in practice is
to choose an arbitrary cutpoint c and take further action if the prediction exceeds c, referred to as a
positive test, and no action if the prediction falls below c, referred to as a negative test. The
discrimination accuracy of the test is reported separately for cancer cases and controls, as the
sensitivity (proportion of cancer cases testing positive) and speciﬁcity (number of controls testing
negative), for various choices of the cutpoint c. The receiver operating characteristic curve plots the
sensitivity versus the false-positive rate (1-speciﬁcity) for all cutpoints c. The area underneath the
receiver operating characteristic curve (AUC) ranges from 0.50 for a test with no discriminative
power to 1.0 for a test with 100% sensitivity at all possible cutpoints c. The AUC holds an
alternative intuitively appealing deﬁnition as the probability that for a randomly drawn cancer case
and randomly drawn control, the case has a higher risk than the control. Deﬁned as such, it is a
rank-based metric equivalent to the non-parametric Wilcoxon test statistic for comparing dis-
tributions in two populations (wilcox.test in R), and can be implemented to test the null
hypothesis that AUC5 0.50 versus the alternative that AUC40.50. The U-statistic approach of
DeLong et al. (1988) can be used for a formal statistical test of the null hypothesis that two risk
tools or markers have the same AUC on a validation set versus the two-sided alternative that they
diﬀer (roc.test function with method ’’Delong’’ and paired5T option, in R package
pROC). The AUC is practically the ubiquitous endpoint in diagnostic medicine and has been nearly
the sole performance criterion for evaluating the PCPTRC (Parekh et al., 2006; Eyre et al., 2009;
Hernandez et al., 2009). However, it only measures one dimension of performance, discrimination,
and even there, recent statistical reports have criticized its use for placing too much weight on the
clinically irrelevant portion of the receiver operating characteristic curve (ROC) (Pencina et al.,
2008; Greenland, 2008).
Calibration assesses how closely predicted risks match actual risks in the population and can also
be assessed among subgroups to better identify where the prediction model is failing. A formal test
of calibration can be implemented by splitting a validation set into k groups, typically k5 10 groups
deﬁned by deciles of the distribution of evaluated risks on the validation set, and using an ap-
proximation to Pearson’s chi-square goodness-of-ﬁt test recommended by Lemeshow and Hosmer
(1982):
X2 ¼
Xk
i¼1
ðOi  nipiÞ2
nipið1 piÞ
;
where Oi is the observed number of cancer cases, ni the number of individuals, and pi the average
risk for the ith group, for i5 1,yk.
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Discrimination and calibration metrics objectively summarize accuracy but do not
provide information as to which thresholds of a prediction model might be useful for basing
clinical decisions. Towards this end, Vickers and Elkin (2006) proposed a measure of net beneﬁt
justiﬁed through a layman’s decision analysis framework that does not rely on user-speciﬁed costs
associated with various outcomes as full-blown decision analyses typically do. The approach relies
on assigning weights to the relative harms of false-positive and negative decisions and then eval-
uating the net beneﬁt as the average beneﬁt of the decisions. Some decision theoretic arguments
show that if a threshold c of a risk prediction is chosen for deciding to take action, such as to get a
prostate biopsy, and the value of a true positive decision is set to 1 for identiﬁability, then the value
of a false-positive decision becomes –c/(1c) (Vickers and Elkin, 2006). As with the other accuracy
measures, net beneﬁt is evaluated on an external cohort to the one on which the risk model was
developed. The net beneﬁt is deﬁned as the average beneﬁt value over the true and false-positive
counts:
NetBenefitðcÞ ¼ TruePositiveCountðcÞ
SampleSize
 FalsePositiveCountðcÞ
SampleSize
c
1 c
 
;
where for emphasis dependency on the user-selected threshold c is included in the deﬁnition. The
expression for the net beneﬁt can be rewritten to show that it is also a function of the discrimination
measures sensitivity, TPR(c), and 1-speciﬁcity, FPR(c), evaluated on the external validation set and
weighted by the proportions of cancer cases (%Cancer) and non-cancer cases (%Non-Cancer) and
their beneﬁt values in the validation set:
NetBenefitðcÞ ¼ TPRðcÞ %Cancer FPRðcÞ %Non-Cancer c
1 c
 
:
The discrimination metrics TPR and FPR already tend to vary by validation set. As the above
expression shows, net beneﬁt further relies on the cancer prevalence in the validation set. In other
words, for two validation sets with the same operating characteristics of a prediction model, the one
with higher cancer prevalence will demonstrate higher net beneﬁt.
Vickers and Elkin (2006) suggested evaluating the net beneﬁt over all possible thresholds c of the
prediction model ranging from 0 to 1, but in the speciﬁc application as the case study here, of
determining whether or not to proceed to prostate biopsy for determination of prostate cancer,
Steyerberg and Vickers (2008) discussed that most men would reasonably be uncertain as to the
course of action with risks in the 10–40% range. Speciﬁc values of the net beneﬁt can be diﬃcult to
interpret in isolation so Vickers and Elkin (2006) also recommended overlaid decision curves for the
strategies of referring no patients to biopsy or all patients to biopsy regardless of the threshold c
selected. For these curves the last expression, c/(1c), remains the same but the TPR and FPR are
calculated based on the test rule that assigns no patients to test positive (in other words, c41) and
all patients to test positive (in other words, co0). For referring no patients to biopsy, the TPR and
FPR are identically 0 so the net beneﬁt curve for this rule is the horizontal line at 0 across all
thresholds c. For the decision rule referring all patients to prostate biopsy the TPR and FPR are 1
and the net beneﬁt curve becomes %Cancer%Non-Cancer c/(1c).
For comparing risk predictions from a new model to risk predictions from an old model, Pencina
et al. (2008) proposed the IDI that is simply the diﬀerence in discrimination slopes between the new
and old predictions as proposed by Yates (1982):
IDI ¼ 1
nevents
Xnevents
i¼1
pnew;i 
1
nnon-events
Xnnon-events
i¼1
pnew;i
 !
 1
nevents
Xnevents
i¼1
pold;i 
1
nnon-events
Xnnon-events
i¼1
pold;i
 !
;
where nevents are the number of events, in this case prostate cancer cases, and nnon-events are the
number of non-events, in this case non-cancer cases, and the summations sum over the predicted
probabilities from the new and old models as subscripted among the cancer cases and non-cases as
subscripted on n’s. The logic of the IDI is clear, a good prediction model should provide higher
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estimated risks among the cancer cases in the validation set compared with the controls, how good
is determined by the discrimination slopes of the models. A positive IDI would indicate a new model
has better discrimination slope than the old.
As a ﬁnal note, all the measures deﬁned above require no missing values for all covariates
appearing in the risk prediction tool, but this is often not the reality for externally collected
validation sets. Janssen et al. (2010) recently showed by simulation that imputation for
missing covariates results in less biased estimates of validation metrics than other practices
of either excluding the entire patient from analysis, or the covariate out of a model. The current
state of the art in imputation is based on speciﬁcation of full conditional distributions for
missing covariates and termed Multivariate Imputation by Chained Equations (MICE),
implementable with the mice package in R (van Buuren, 2007). MICE can be used without
additional model speciﬁcations to impute missing data under a missing-at-random (MAR) me-
chanism and with additional speciﬁcations to impute missing data assumed to be
not-MAR (NMAR). Brieﬂy the method works by ﬁtting an appropriate conditional model,
such as a logistic model for dichotomous variables, for all missing variables conditional on all other
variables, outcomes and covariates, in the model. The R mice package recommends using all
measured variables in a data set to build the imputation model even if they are not part of the
analysis.
4 Case study: updating the PCPTRC
The online PCPTRC was established based on logistic regression on data from 5519 placebo arm
participants in the PCPT; full details on the patient inclusion and model selection procedures can be
found in Thompson et al. (2006). Let X5 (1, log(PSA), DRE, FamHist, PriorBiop)0 be a ﬁve-
dimensional vector of covariates plus intercept term for an individual man, with PSA recorded in
ng/mL, log denoting the natural logarithm, DRE5 1 for an abnormal digital rectal exam that is
suspicious for cancer versus 0 otherwise, FamHist5 1 for a recorded history of prostate cancer in a
father, brother or son and 0 otherwise, and Priorbiop5 1 if ever a prior biopsy was performed that
was negative for prostate cancer and 0 otherwise (note the PCPTRC is not valid for persons with
either a prior positive prostate biopsy or any prior diagnosis of prostate cancer). Let the vector b
represent the estimated log odds ratios from the logistic regression used to ﬁt the PCPTRC: b5
(1.797, 0.849, 0.905, 0.269, 0.448)0 (Thompson et al., 2006). From the signs of these log odds
ratios, higher PSA, an abnormal DRE and a positive family history increased the odds of prostate
cancer, while a prior negative prostate biopsy decreased the odds; for interpretation of the mag-
nitudes see Thompson et al. (2006).
Liang et al. (2011) reported on the operating characteristics of 10 potential prostate
cancer biomarkers recorded on 227 prostate cancer cases and 247 age- and race-matched
controls identiﬁed in the SABOR screening cohort. Of the 10 markers studied only two were
statistically signiﬁcantly and independently diﬀerentiated between cases and controls:[-2]proPSA
was higher among cancer cases and %freePSA was lower (both p-valueso0.001, Table 1).
This evidence suggested these two markers might be worthwhile candidate markers for augmenting
the PCPTRC.
Figure 1 shows a joint scatterplot of the two markers for the 227 prostate cancer cases and 247
controls on the logarithmic scale. Although there is overlap, prostate cancer cases tended to have
higher levels of [-2]proPSA and lower levels of %freePSA. Chi-square plots, the generalization of
normal probability plots for multivariate outcomes, suggested some potential departures from
multivariate normality caused by a handful of outliers for both the cases and controls (data not
shown). These are seen on the left side of Fig. 1, with the four prostate cancer cases with [-2]proPSA
values exceeding 100 pg/mL, a handful of controls with %freePSA very low and one with an
outlying low [-2]proPSA value in addition. As the number of potential outliers was small and there
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were no recorded reasons they might be in error it was decided to pursue the multivariate normal
regression under a potential slight violation of the normal assumption rather than a more robust
modeling approach to handle the outliers.
Separate model selection procedures based on Wilk’s lambda test were performed for the
bivariate regression of marker pairs (log%freePSA, log[-2]proPSA) on the risk factors logPSA,
DRE, FamHist (family history), PriorBiop (prior biopsy), Age and Race (African american versus
other) in the SABOR cases and controls. In other words, the additional predictors Age and Race
were considered for the models in the likelihood ratio compared with the four predictors in the prior
risk model (X) and it was not required that all components in the prior risk model be included in
models for the likelihood ratio. Component models of the likelihood ratio and prior odds have
diﬀerent endpoints and it is not expected that the same factors would aﬀect both. This procedure
resulted in the covariates logPSA and Age being included in the multivariate regressions for the
controls and cases. The multivariate generalization of the squared sum of residuals divided by the
degrees of freedom was used to estimate the variance-covariance matrices for the distribution of
(log%freePSA, log[-2]proPSA) in cases and controls, resulting in the following expressions for
Table 1 Characteristics of participants in the SABOR and EDRN case–control studies.
Characteristic SABOR EDRN
Cases Controls Cases Controls
N5 227 N5 247 N5 251 N5 324
Age (years)V Mean (SD) 64.1 (8.4) 64.2 (8.6) 63.4 (9.3) 60.5 (7.8)
Range 44–89 45–84 41–93 42–80
Race, N (%)D White 129 (56.8) 167 (67.6) 216 (86.1) 276 (85.2)
Black 32 (14.1) 35 (14.2) 21 (8.4) 24 (7.4)
Other 66 (29.1) 45 (18.2) 8 (3.2) 18 (5.6)
Unknown 0 (0.0) 0 (0.0) 6 (2.4) 6 (1.9)
Prior negative biopsy, N (%) Never 177 (78.0) 203 (82.2) 251 (100.0) 324 (100.0)
At least one 50 (22.0) 44 (17.8) 0 (0.0) 0 (0.0)
Digital rectal exam, N (%)D Normal 160 (70.5) 240 (97.2) 190 (75.7) 261 (80.6)
Abnormal 67 (29.5) 7 (2.8) 61 (24.3) 59 (18.2)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 4 (1.2)
Family history, N (%)D No 171 (75.3) 219 (88.7) 173 (68.9) 233 (71.9)
Yes 56 (24.7) 28 (11.3) 65 (25.9) 75 (23.1)
Unknown 0 (0.0) 0 (0.0) 13 (5.2) 16 (4.9)
PSA, ng/mLD,V Mean (SD) 5.1 (8.8) 1.5 (1.3) 10.6 (26.3) 4.5 (3.1)
Range 0.3–93.8 0.1–8.4 0.7–310.6 0.3–18.2
[-2]proPSA, pg/mLD,V Mean (SD) 18.1 (34.5) 8.9 (5.7) 32.7 (128.0) 12.1 (10.4)
Range 2.3–447.9 0.8–39.0 3.9–1831.7 2.2–133.9
%freePSAD,V Mean (SD) 21.6 (11.6) 31.9 (11.6) 17.4 (10.4) 23.4 (10.6)
Range 4.4–72.0 6.6–73.0 3.7–78.9 6.4–64.8
Dif p-valueo0.05 between cases and controls in SABOR. Vif p-value o 0.05 between cases and controls in EDRN.
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terms comprising the likelihood ratio LR:
Y ¼ðlog%freePSA; log½2proPSAÞ0
mcancer ¼
2:667 0:365 log PSA10:011Age
1:38510:627 log PSA10:006Age
 
cancer ¼
0:179 0:121
0:121 0:231
 
mno cancer ¼
3:276 0:235 log PSA10:002Age
2:43810:571 log PSA 0:008Age
 
no cancer ¼
0:128 0:097
0:097 0:188
 
:
With these parameter values substituted in, LRs become a function of a patient’s age, PSA,
%freePSA and [-2]proPSA values. LRs greater than 1 represent conﬁgurations of these char-
acteristics that inﬂate posterior risks of prostate cancer greater than PCPTRC risks, LRs less than 1
represent conﬁgurations that diminish posterior risks compared with prior risks, and LRs equal
to 1, situations where the addition of the new markers %freePSA and [-2]proPSA do not alter prior
risks. LR surfaces as a function of %freePSA and [-2]proPSA for a 65-year-old man with PSA
2.0 ng/mL versus a 65-year-old man with PSA 5.0 ng/mL are shown in Fig. 2, where the axes have
been chosen to reﬂect contours of the marker pairs near values of LRs of 1, meaning no preference
for cancer case versus control assignment. For both scenarios, LRs are highest for low %freePSA
and high [-2]proPSA values, but speciﬁc pairs of %freePSA and [-2]proPSA yield diﬀerent LRs for
lower versus higher PSA values as seen by comparison of Fig. 2A and B.
5 Case study: Validation of the updated PCPTRC
The EDRN validation cohort is also listed in Table 1 and comprised 575 men who presented at
multiple urologic facilities in the northeastern part of the U.S. with clinical symptoms, and was
previously reported on by Sokoll et al. (2010). As seen in Table 1, none of the men in the cohort ever
Figure 1 Scatterplots of %freePSA (in percent) and [-2] proPSA (in pg/mL) for the 227 SABOR
prostate cancer cases and 247 SABOR controls.
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had a prior biopsy. Only the discrete risk factors, race, DRE, and family history, had any missing
values in the EDRN validation set, and these were very modest (approximately 2% for race and
DRE and 5% for family history). Multiple imputation via chained equations was peformed under a
MAR hypothesis for missing data, by specifying logistic regressions for race, DRE, and family
history conditional on all other variables in Table 1 except for prior biopsy, along with prostate
cancer status as covariates. The number of iterations was set to 20 and ﬁve imputed data sets were
retained for analysis. Any validation summaries requiring imputation were averaged over these ﬁve
data sets, thus resulting in ranges for some sample sizes.
Figure 3 shows ROCs for updated posterior PCPTRC risks (AUC5 0.698, 95% CI5
0.655–0.741), %freePSA (AUC5 0.693, 95% CI5 0.649–0.736), PCPTRC risks (AUC5 0.677,
95% CI5 0.634–0.721), PSA (AUC5 0.663, 95% CI5 0.619–0.707), and [-2]proPSA (AUC5
0.648, 95% CI5 0.604–0.693) evaluated on the EDRN validation set. There were no statistical
diﬀerences between any of the AUCs as assessed by paired AUC tests (all p-values40.05). Re-
stricting to the clinically relevant part of the AUC curve, the portion with FPRs less than 20%,
revealed that posterior PCPTRC risks had the highest sensitivities for FPRs o10%, followed by
prior PCPTRC risks, but in the region of FPRs ranging from 10 to 20%, %freePSA obtained the
Figure 2 Contour plots of estimated likelihood ratios for a 65-year-old man with PSA value
2.0 ng/mL (A) and 5.0 ng/mL (B).
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same sensitivities as both PCPTRC and posterior PCPTRC risks (Table 2). McNemar’s test per-
formed at the 0.05 level of statistical signiﬁcance revealed no diﬀerences between sensitivities be-
tween the posterior PCPTRC risks and PCPTRC risks, nor between posterior PCPTRC risks and
%freePSA, at all FPRs listed in Table 2.
The average PCPTRC risk and updated PCPTRC posterior risk among the 575 participants in
the EDRN validation set were 43.1% (95% CI 41.8–44.4%) and 45.9% (95% CI 44.0–47.8%),
respectively, indicating that posterior risks were higher than prior risks on average in the cohort.
The actual proportion of the EDRN cohort that had prostate cancer, 43.7% (95% CI 39.6–47.8%),
indicated the possibility however that posterior PCPTRC risks could be overestimating and
PCPTRC risks underestimating actual risks, a problem with calibration-in-the-large as termed in
Steyerberg (2010). Table 3 reveals that this tendency of the posterior PCPTRC risk to overestimate
actual risks occurred across many subpopulations. For most of the risk categories, average pos-
terior PCPTRC risks tended to overestimate actual risks, although the 95% CIs did overlap. For the
subgroup with [-2]proPSA 15 pg/mL or less, average posterior PCPTRC risks were statistically
signiﬁcantly higher than the actual rate of prostate cancer in the subgroup: 44.7% (95% CI
42.6–46.8%) compared with 37.6% (95% CI 32.9–42.3%), respectively.
The poor calibration of posterior PCPTRC risks to actual risks is more formally borne out in
Table 4, where the 575 members of the EDRN cohort have been grouped according to deciles of
Figure 3 ROCs for the EDRN validation set.
Table 2 Sensitivities in percent [thresholds of marker or risk tool in respective units] obtained in
the EDRN validation set for false-positive rates (FPR) 5, 10, 15 and 20%.
Marker or tool (units) FPR 5% FPR 10% FPR 15% FPR 20%
Posterior PCPTRC risk (%) 26.7 [75.1] 33.1 [66.9] 39.4 [58.7] 45.0 [54.7]
PCPTRC risk (%) 21.9 [62.2] 28.7 [55.8] 33.5 [52.1] 40.6 [48.4]
PSA (ng/mL) 14.7 [10.8] 21.9 [8.4] 32.7 [6.8] 39.8 [6.1]
[-2]proPSA (pg/mL) 13.9 [28.3] 25.1 [21.6] 32.7 [17.7] 37.8 [15.7]
%freePSA (%) 19.5 [9.8] 33.9 [11.9] 43.4 [13.4] 49.4 [14.6]
For all markers except %freePSA, values above the threshold indicate a positive test; for %freePSA values at or below the
threshold indicate a positive test.
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their PCPTRC posterior risk values. In only 4 out of the 10 decile groups did actual proportions of
prostate cancer fall within the bounds of the predicted PCPTRC risks, a statistically signiﬁcant
rejection of goodness-of-ﬁt according to the Hosmer–Lemeshow test (p-value5 0.003).
The discrimination slope or average diﬀerence between predicted risks between cancer and non-
cancer cases for the upgraded PCPTRC model on the EDRN validation set was 16.8%, a modest
improvement over the 10.5% for the original PCPTRC. The diﬀerence, or IDI, was statistically
signiﬁcantly diﬀerent from 0 (6.3%, 95% CI 3.0–9.6%). The net beneﬁt curves in Fig. 4 indicated
beneﬁt of using both the PCPTRC prior and posterior risks over the blanket rule of referring all
men in the EDRN cohort to prostate biopsy for thresholds exceeding 20%, but no clear beneﬁt of
the more complicated posterior PCPTRC risks over the prior PCPTRC risks in the region of risks
between 10 and 40% of most clinical relevance to men deciding on whether to pursue prostate
Table 3 Comparisons of prior and posterior PCPTRC risks to observed prostate cancer rates in
the EDRN for various subgroups
Subgroup (sample size
range across imputed
data sets)
Prostate cancer
(%)
[95% CI]
Average PCPTRC
risk (%)
[95% CI]
Average posterior
PCPTRC
risk (%) [95% CI]
All (575) 43.7 43.1 45.9
[39.6, 47.8] [41.8, 44.4] [44.0,47.8]
PSA 4ng/mL or less (242) 32.2 31.7 37.4
[26.3, 38.1] [30.4, 32.9] [35.1, 39.8]
PSA greater than 4 ng/mL (333) 52 51.4 52.1
[46.6, 57.4] [49.9, 52.9] [49.5, 54.7]
DRE normal (454–455) 41.9 40.1 42.7
[37.3, 46.4] [38.9, 41.3] [40.7, 44.7]
DRE abnormal (120–121) 50.6 54.2 58.2
[41.6, 59.5] [50.7, 57.7] [54.1, 62.3]
Race other (527–530) 43.3 42.7 45.7
[39.1, 47.6] [41.4, 44.0] [43.8, 47.7]
Race black (45–48) 47.4 48 48.5
[33.0, 61.8] [42.3, 53.8] [41.3, 55.8]
Age 65 years or older (214) 52.3 47.5 46
[45.6, 59.0] [45.5, 49.6] [43.1, 48.9]
Age younger than 65 (361) 38.5 40.5 45.9
[33.5, 43.5] [38.9, 42.0] [43.4, 48.4]
Family history (147–155) 46.9 44.7 48
[38.9, 54.9] [42.3, 47.1] [44.5, 51.6]
No family history (420–428) 42.5 42.5 45.2
[37.8, 47.2] [41.0, 44.1] [43.0, 47.4]
[-2]proPSA 15 pg/mL or less (402) 37.6 38.1 44.7
[32.9, 42.3] [36.9, 39.4] [42.6, 46.8]
[-2]proPSA greater than 15 pg/mL (173) 57.8 54.6 48.8
[50.4, 65.2] [52.1, 57.0] [44.7, 52.9]
%freePSA 20 or less (309) 56 46.7 58.9
[50.5, 61.5] [45.0, 48.4] [56.5, 61.3]
%freePSA greater than 20 (266) 29.3 38.9 30.9
[23.8, 34.8] [37.0, 40.7] [29.2, 32.6]
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biopsy as referenced by Steyerberg and Vickers (2008). Across all thresholds, both the PCPTRC and
posterior PCPTRC rules provided beneﬁt over the rule referring no patients to biopsy.
6 Concluding remarks
This case study illustrated a simple analytical update to the original PCPTRC incorporating
%freePSA and [-2]proPSA, and accompanying R code for the formulas are available as Supporting
Information and posted online at the PCPTRC website. The methodology was based on estimating
likelihood ratios based on multivariate normal distributions applied separately to data from cancer
cases and controls obtained from an external case–control study to that used to build the prior
PCPTRC model. Retrospective case-control designs are much more eﬃcient than prospective co-
hort studies for studying relationships between markers and cancer, so the methodology optimizes
Table 4 Comparisons of posterior PCPTRC risks to observed prostate cancer rates in the EDRN
by deciles of posterior PCPTRC risks used in calculation of the Lemeshow–Homer test of goodness-
of-ﬁt.
Posterior PCPTRC risk range (%) Proportion of EDRN cohort with prostate cancer
2.1–21.7 15.5
21.7–25.7 26.3
25.7–30.4 41.4
30.4–34.7 26.3
34.7–40.3 41.4
40.3–46.4 43.9
46.4–55.6 49.1
55.6–66.8 48.3
66.8–82.9 57.2
82.9–99.9 86.2
Sample sizes in each category were either 57 or 58.
Figure 4 Net beneﬁt curves for the EDRN validation set.
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incorporation of new information for upgrading the PCPTRC. Towards a diﬀerent objective of
evaluating the diagnostic accuracy of new markers, Janssens et al. (2005) and Gu and Pepe (2009,
2011) have proposed an alternative method for estimating log likelihood ratios as the diﬀerence
between the log posterior and prior odds, with logistic regressions used for both. This approach has
some simplicity in modeling assumptions since only the disease outcome is modeled but is tailored
to the situation where the new and old markers are measured on the same data set, not where a
considerably sized cohort has been used to build the prior odds and a smaller more eﬃcient
case–control study is all that is available for the new markers as is the case here.
Formulated as a more general problem for updating an existing risk model founded on logistic
regression to apply to new settings, for example, to adapt risk tools to changes of grading systems
for tumors, or new geographic regions, and/or to include new markers, Chapters 20 and 21 of
Steyerberg (2010) contain an excellent review of the many frequentist and empirical Bayes meth-
odologies that have recently come under study. For example, if one risk model is to be extended to a
population known to have a higher prevalence of disease, an updating methodology for the in-
tercept in the logistic regression is proposed, incorporating prior information from other sources,
and with shrinkage in order to not overﬁt to the new data. Due to the small SABOR data set used to
form the likelihood ratio, some shrinkage might also improve the poor calibration performance,
and special ﬁxes among subpopulations might be warranted for some of the subgroups of patients
in Table 3. These very interesting directions warrant further detailed study through simulation and
collection of more data. Additionally, continual dynamic updating of risk models as new data ﬂow
in are another topic of increased attention due to their practical need (Steyerberg, 2010). For
example, we expect new case–control studies for %freePSA and [-2]proPSA to soon become
available, as these markers are becoming more widely used. It might be prudent then to shift the
EDRN validation set to become a joint development data set with SABOR and make space for the
more recently available data to be used as the new validation set. This incurs new methodologic
challenges for combining multiple data sets, potentially requiring the introduction of random eﬀects
(Steyerberg, 2010).
A limitation to likelihood ratios modeled as ratios of probability density functions is that they are
unstable in areas where the control density in the denominator has a smaller tail than the case density
in the numerator, causing the denominator to approach 0 and the likelihood ratio and hence pos-
terior risks to explode. This occurs for some conﬁgurations of the covariates and markers. Similar
problems occur with other risk prediction models so it is routine practice to bound risks reported on
the PCPTRC website at 75% (the returned output is a message that the risk exceeds 75% with no
conﬁdence interval reported). The problem can be alleviated somewhat by constraining the variances
for cancer cases and controls to be the same, which also will help monotonicity of the likelihood ratio
(that for a marker elevated in cancer cases, the likelihood ratio will monotonically increase). Un-
fortunately this constraint does not match science, however, as even after transformation, markers
are typically much more dispersed in cancer cases compared to controls. More research is needed
into taming the likelihood ratios to ﬁnd a balance between accurate modeling of marker distributions
among cancer cases and controls and stability of outcome.
Our method assumed marker distributions could be transformed to multivariate normality in
cancer cases and controls, which retains a nice analytical formula for posterior risks. However,
typically, as was the case in the data set of this study, the observed markers contain potential
outliers and/or skewness in their distribution. Furthermore there could conceivably be clusters
among the diseased and non-diseased populations, identiﬁable with suﬃciently large sample sizes.
Multivariate skew t mixture distributions pose a nice framework for handling these issues and
estimation-maximization algorithms are available for ﬁtting (Fru¨hwirth-Schnatter and Pyne, 2010).
Additionally they contain multivariate normal, skew normal, t and skew t as special cases. Due to
the small sample sizes in this study it was not anticipated the extensions would make much of a
diﬀerence, but it is a worthy route of investigation for future studies to upgrade the PCPTRC.
Additional extensions are needed for scenarios where the markers to be incorporated are not all
Biometrical Journal 54 (2012) 1 139
r 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
continuous, but rather mixtures of categorical and continuous variables, or where multiple external
case–control studies are combined, potentially warranting a random-eﬀects or meta-analysis type
approach.
Validation on the EDRN validation cohort, a more clinical cohort with higher PSA values than
the SABOR cohort, indicated however, no clear advantages of posterior PCTPRC risks that
incorporate the two less easily obtainable markers to the standard PCTPRC in terms of net beneﬁt,
calibration nor discrimination, and also no clear improvement in discrimination over just using one
of the markers, %freePSA. Interestingly, a referee pointed out that the strong correlation
between logarithms of the two markers in the estimated multivariate normal models for cancer
cases (correlation 0.595) and controls (0.789) might actually be diminishing performance of the
posterior PCPTRC as compared with just using the stronger of the two correlated markers,
%freePSA, to upgrade the PCPTRC. We investigated this possibility by just using the marginal
univariate normal distribution for log %freePSA implied by the ﬁtted bivariate normal model and
evaluated marginal posterior risks based on just this marker. We were surprised by the results: the
estimated AUC of marginally upgraded PCPTRC was 0.722, just a minor 0.02 increase above the
AUC of the posterior PCPTRC (AUC5 0.698), but enough to be statistically signiﬁcantly better
than the posterior PCPTRC (p-value5 0.02) and %freePSA (p-value5 0.03). Clinically, this is a
pleasing ﬁnding since %freePSA is a much more widely available marker than [-2]proPSA,
and the resulting calculator is simpler to implement. Statistically, it points out that the same
parsimonious model-building principles that would automatically be applied when introducing new
markers as covariates into a logistic model would also apply for their incorporation into risk
prediction tools through likelihood ratios. In other words, one should consider model selection on
the number of new markers modeled as outcomes in the likelihood ratios by investigating subsets
of markers.
Reports of a single validation cohort should not be taken as the ﬁnal word on a risk prediction
tool as even for the most studied marker of prostate cancer, PSA, reports of its AUC have ranged
from no predictive power 0.525 (Nguyen et al., 2010), to decent predictive power, 0.678 (Thompson
et al., 2005), to remarkable power, 0.840 (Liang et al., 2011). For this reason, it is critical that risk
tools be published online to facilitate a spectrum of validations. An advantage to transparent
analytical formulas underpinning risk models, such as the likelihood ratio approach adopted in this
article, is that they foster multiple external validations, the collective experience of which can
ultimately judge whether or not and for which populations a tool should be used. An additional
advantage of posting risk tools online is that they transport state-of-the-art medicine to even remote
corners of the world, to small community clinics and to their patients.
Acknowledgements This research was supported by National Institutes of Health grants CA086402,
CA054174, CA86323, UO1CA113913, EDRN grant CA115102, and a National Cancer Institute Cancer
Center support grant to the UTHSCSA CTRC: 5P30 CA0541474-18. The authors thank the SABOR and
EDRN participants.
Conﬂict of interest
The authors have declared no conﬂict of interest.
References
Ankerst, D. P., Groskopf, J., Day, J. R., Blase, A., Rittenhouse, H., Pollock, B. H., Tangen, C., Parekh, D.,
Leach, R. J. and Thompson, I. (2008). Predicting prostate cancer risk through incorporation of prostate
cancer gene 3. Journal of Urology 180, 1303–1308.
Anscombe, F. J. (1967) Topics in the investigation of linear relations ﬁtted by the method of least squares (with
discussion). Journal of the Royal Statistical Society Series B 29, 1–52.
140 D. P. Ankerst et al.: Updating risk prediction tools
r 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
Chatﬁeld, C. (1995). Model uncertainty, data mining, and statistical inference (with discussion). Journal of the
Royal Statistical Society Series A 158, 419–466.
DeLong, E. R., DeLong, D. M. and Clarke-Pearson, D. L. (1988). Comparing the areas under two or more
correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–845.
Eyre, S. J., Ankerst, D. P., Wei, J. T., Nair, P. V., Regan, M. M., Bueti, G., Tang, J., Rubin, M. A., Kearney, M.,
Thompson, I. M. and Sanda, M. G. (2009). Validation in a multiple urology practice setting of the Prostate
Cancer Prevention Trial calculator for predicting prostate cancer detection. Journal of Urology 182, 2653–2658.
Fru¨hwirth-Schnatter, S. and Pyne, S. (2010). Bayesian interface for ﬁnite mixtures of univariate and multi-
variate skew-normal and skew-t distributions. Biostatistics 11, 317–336.
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C. and Mulvihill, J. J. (1989).
Projecting individualized probabilities of developing breast cancer for white females who are being ex-
amined annually. Journal of the National Cancer Institute 81, 1879–1886.
Gail, M. H., Costantino, J. P., Pee, D., Bondy, M., Newman, L., Selvan, M., Anderson, G. L., Malone, K. E.,
Marchbanks, P. A., McCaskill-Stevens, W., Norman, S. A., Simon, M. S., Spirtas, R., Usin, G. and
Bernstein, L. (2007). Projecting individualized absolute invasive breast cancer risk in African American
women. Journal of the National Cancer Institute 99, 1782–1792.
Greenland, S. (2008). The need for reorientation toward cost-eﬀective prediction: comments on ‘Evaluating the
added predictive ability of a new marker: from area under the ROC curve to reclassiﬁcation and beyond’
by M. J. et al., Statistics in Medicine. Statistics in Medicine 27, 199–206.
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, B. Jr., Clark, L. T., Hunninghake, D. B., Pasternak,
R. C., Smith, S. C. and Stone, N. J. for the Coordinating Committee of the National Cholesterol Edu-
cation Program (2004). Implications of recent clinical trials for the National Cholesterol Education
Program Adult Treatment Panel III Guidelines. Circulation 110, 227–239.
Gu, W. and Pepe, M. S. (2009). Estimating the capacity for improvement in risk prediction with a marker.
Biostatistics 10, 172–186.
Gu, W. and Pepe, M. S. (2011). Estimating the diagnostic likelihood ratio of a continuous marker. Biostatistics
12, 87–101.
Hernandez, D. J., Han, M., Humphreys, E. B., Mangold, L. A., Taneja, S. S., Childs, S. J., Bartsch, G. and
Partin, A. W. (2009). Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-
based model, the prostate cancer risk calculator, and prostate-speciﬁc antigen level alone. British Journal
Urology International 103, 609–614.
Izenman, A. J. (2008). Modern Multivariate Statistical Techniques. Springer, New York.
Janssen, K. J. M., Donders, A. R. T., Harrell, F. E. Jr., Vergouwe, Y., Chen, Q., Grobbee, D. E. and Moons,
K. G. M. (2010). Missing covariate data in medical research: To impute is better than to ignore. Journal of
Clinical Epidemiology 63, 721–727.
Janssens, A. C. J. W., Deng, Y., Borsboom, G. J. J. M., Eijkemans, M. J. C., Habbema, J. D. F. and
Steyerberg, E. W. (2005). A new logistic regression approach for the evaluation of diagnostic test results.
Medical Decision Making 25, 168–177.
Lemeshow, S. and Hosmer, D. W. Jr., (1982). A review of goodness of ﬁt statistics for use in the development
of logistic regression models. American Journal of Epidemiology 115, 92–106.
Liang, Y., Ankerst, D. P., Ketchum, N. S., Ercole, B., Shah, G., Shaughnessy, J. D. Jr., Leach, R. J. and
Thompson, I. M. (2011). Prospective evaluation of operating characteristics of prostate cancer detection
biomarkers. Journal of Urology 185, 104–110.
Nguyen, C. T., Yu, C., Moussa A., Kattan, M. W. and Jones, J. S. (2010). Performance of prostate cancer
prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by
extended prostate biopsy. Journal of Urology 183, 529–533.
Parekh, D. J., Ankerst, D. P., Higgins, B. A., Hernandez, J., Canby-Hagino, E., Brand, T., Troyer, D., Leach,
R. and Thompson, I. M. (2006). External validation of the Prostate Cancer Prevention Trial risk calcu-
lator. Urology 68, 1152–1155.
Pencina, M. J., D’Agostino Sr., R. B., D’Agostino Jr., R. B., Vasan, R. S. (2008). Evaluating the added
predictive ability of a new marker: from area under the ROC curve to reclassiﬁcation and beyond.
Statistics in Medicine 27, 157–172.
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M. and Yasui, Y.
(2001). Phases of biomarker development for early detection of cancer. Journal of the National Cancer
Institute 93, 1054–1061.
Biometrical Journal 54 (2012) 1 141
r 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
Skates, S. J., Pauler, D. K. and Jacobs, I. J. (2001). Screening based on the risk of cancer calculation from
Bayesian hierarchical change-point models of longitudinal markers. Journal of the American Statistical
Association 96, 429–439.
Sokoll, L. J., Sanda, M. G., Feng, Z., Kagan, J., Mizrahi, I. A., Broyles, D. L., Partin, A. W., Srivasta, S.,
Thompson, I. M., Wei, J. T., Zhang, Z. and Chan, D. W. (2010). A prospective, multicenter National
Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer
detection and correlating with cancer aggressiveness. Cancer Epidemiology, Biomarkers and Prevention 19,
1193–1200.
Steyerberg, E. W. and Vickers, A. J. (2008). Decision curve analysis: a discussion.Medical Decision Making 28,
146–149.
Steyerberg, E. W., Vickers, A. J., Cook, N. R., Gerds, T., Gonen, M., Obuchowski, N., Pencina, M. J. and
Kattan, M. W. (2010). Assessing the performance of prediction models, a framework for traditional and
novel measures. Epidemiology 21, 128–138.
Steyerberg, E. W. (2010). Clinical Prediction Models. Springer, New York.
Thompson, I. M., Ankerst, D. P., Chi, C., Lucia, M. S., Goodman, P., Crowley, J. J., Parnes, H. L. and
Coltman Jr., C. A. (2005). The operating characteristics of prostate-speciﬁc antigen in a population with
initial PSA of 3. 0 ng/mL or lower. Journal of the American Medical Association 294, 66–70.
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes,
H. L. and Coltman Jr., C. A. (2006). Assessing prostate cancer risk: results from the Prostate Cancer
Prevention Trial. Journal of the National Cancer Institute 98, 529–534.
van Buuren, S. (2007). Multiple imputation of discrete and continuous data by fully conditional speciﬁcation.
Statistical Methods in Medical Research 16, 219–242.
Vickers, A. J. and Elkin, E. B. (2006). Decision curve analysis: a novel method for evaluating prediction
models. Medical Decision Making 26, 565–574.
Wolf, A. M. D., Wender, R. C., Etzioni, R., Thompson, I. M., D’Amico, A. V., Volk, R. J., Brooks, D. D.,
Dash, C., Guessous, I., Andrews, K., DeSantis, C. and Smith, R. A. (2010). American Cancer Society
guideline for the early detection of prostate cancer: update 2010. CA Cancer Journal for Clinicians 60,
70–98.
Yates, J. F. (1982). External correspondence: decomposition of the mean probability score. Organizational
Behavior and Human Performance 30, 132–156
142 D. P. Ankerst et al.: Updating risk prediction tools
r 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
